No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 11.1x · 10Y median 13.8x · 18th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 14
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:21:25.874Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T22:21:25.874Z. Latest historical point 2025-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T22:21:25.874Z. Latest historical point 2025-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T22:21:25.874Z. Latest historical point 2025-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T22:21:25.874Z. Latest historical point 2025-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Citius Oncology, Inc. (CTOR) stock was $0.85 as of Oct 6, 2026, 4:00 PM EDT, down 2.69% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -53.6%
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types.
Medical - Pharmaceuticals · Cranford, NY
Next Earnings Date
Dec 17, 2026
72 days away
EPS Estimate
-0.19
Revenue Est.
$5.77M
Last Quarter Results
EPS
$-0.08
vs Estimate
$-0.07
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CTOR | $79.03M | $0.85 | -2.69% | -53.61% | N/A | N/A | N/A |
| 2VTVT | $78.59M | $30.03 | -0.99% | +25.71% | -13.55% | -19.77% | vs CTOR |
| 3ACRV | $79.61M | $1.86 | -6.06% | +3.65% | N/A | N/A | vs CTOR |
| 4SERA | $78.29M | $2.05 | +2.50% | -38.32% | -28.91% | N/A | vs CTOR |
| 5INO | $78.07M | $1.13 | -1.74% | -52.51% | -57.05% | -36.78% | vs CTOR |
| 6HUMA | $80.30M | $0.48 | -4.40% | -76.03% | -45.73% | N/A | vs CTOR |
forward FY estimate
8.50
$1.49M
vs Estimate
$2.50M
Consensus Rating
Based on 1 analyst
Average Price Target
$4.00
+370.6% upside
Low
$4.00
Current
$0.85
High
$4.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Quarter ending Dec 2026 | $0.10 | $0.10 | $0.10 | 1 |
| Quarter ending Mar 2027 | $0.04 | $0.04 | $0.04 | 1 |
| Quarter ending Jun 2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.56 | $-0.56 | $-0.56 | 1 |
| FY 2027 | $0.10 | $0.10 | $0.10 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $5.77M | $5.77M | $5.77M | 1 |
| Quarter ending Dec 2026 | $14.27M | $14.27M | $14.27M | 1 |
| Quarter ending Mar 2027 | $20.93M | $20.93M | $20.93M | 1 |
| Quarter ending Jun 2027 | $28.55M | $28.55M | $28.55M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Sep 30, 2027, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $13.88M | $13.88M | $13.88M | 1 |
| FY 2027 | $95.16M | $95.16M | $95.16M | 1 |
